AstraZeneca is partnering with US group Seres Therapeutics to investigate use of the body’s microbiome to improve cancer immunotherapy.
News
Chemistry professionals say no-deal Brexit negative for UK science
An international survey commissioned by the Royal Society of Chemistry has revealed the scale of Brexit concern in the sector across the UK, EU and beyond.
UK will be ‘less attractive’ for clinical research post Brexit
More than half of US biotech executives believe that the UK will be a ‘less attractive’ country for conducting clinical trials after Brexit, indicates new research.
NICE u-turn backs use of Darzalex combo for myeloma relapse
Myeloma patients in England are set to gain NHS access to a new second-line treatment combination following a first relapse of the disease.
SMC says ‘no’ to Novartis’ Kymriah for adults with lymphoma
Adults with lymphoma will not be able to access Novartis’ CAR-T therapy Kymriah on the NHS in Scotland after cost-regulators rejected funding for the treatment in this setting.
Takeda’s Entyvio bests AbbVie’s Humira in ulcerative colitis trial
Takeda’s Entyvio has beaten AbbVie’s Humira on achieving clinical remission in patients with ulcerative colitis, in the first trial to directly compare the efficacy and safety of two commonly used biologics for the disease.
Allergan files anti-CGRP migraine drug in the US
US regulators have accepted for review Allergan’s application to market ubrogepant for the acute treatment of migraine.
Gov’t offers £56m for research into public health challenges
Health Minister Nicola Blackwood has announced up to £56 million funding for research into the biggest challenges facing public health – climate change, air pollution, antimicrobial resistance and global pandemics.
Public unaware of how to verify legitimacy of online pharmacies, survey finds
Millions of people in the UK could be putting their health at risk because they do not know how to check the safety of medicines they bought online, suggest findings of a new survey.
NICE nod for Almirall’s Ilumetri, UCB’s Cimzia
NICE has recommended Almirall’s Ilumetri and UCB’s Cimzia as treatment options for severe plaque psoriasis in final draft guidelines.
Roche and Genentech take global macular degeneration step
Roche and Genentech have initiated two large global Phase III clinical trials testing the potential of faricimab in wet age-related macular degeneration.
Positive results for monthly HIV drug
Johnson & Johnson/ViiV’s once-monthly, injectable drug combination for HIV shows comparable efficacy to daily oral treatment in two trials.
Darolutamide submitted for EU approval
Orion Corporation and Bayer have submitted a marketing application in Europe for use of darolutamide in patients with a certain type of prostate cancer.
Study shows reduced hypoglycaemia after switch to Tresiba
Novo Nordisk’s Tresiba has been found to be efficient in treating diabetes compared to other basal insulins.
FDA grants Dupixent Priority Review for sinusitis
US regulators have accepted Sanofi’s Dupixent for Priority Review as a treatment for rhinosinusitis with nasal polyps.
